These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29545396)

  • 1. Exploring New Cardiovascular Pathways: Are Soluble Guanylate Cyclase Stimulators the Right Direction?
    Michalak M; Armstrong PW
    Circ Heart Fail; 2018 Mar; 11(3):e004813. PubMed ID: 29545396
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition.
    Andersen A; Nielsen JM; Holmboe S; Vildbrad MD; Nielsen-Kudsk JE
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):167-73. PubMed ID: 23575263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle.
    Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E
    Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure.
    Liang WL; Liang B
    Curr Cardiol Rep; 2023 Jun; 25(6):607-613. PubMed ID: 37079245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle.
    Báu FR; Mónica FZ; Priviero FB; Baldissera L; de Nucci G; Antunes E
    Eur J Pharmacol; 2010 Jul; 637(1-3):171-7. PubMed ID: 20399768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of soluble guanylyl cyclase activity by oestradiol and progesterone in the hypothalamus but not hippocampus of female rats.
    Reyna-Neyra A; Sarkar G; Etgen AM
    J Neuroendocrinol; 2007 Jun; 19(6):418-25. PubMed ID: 17388815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
    Sandner P; Stasch JP
    Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
    Decaluwé K; Pauwels B; Boydens C; Thoonen R; Buys ES; Brouckaert P; Van de Voorde J
    J Sex Med; 2017 Feb; 14(2):196-204. PubMed ID: 28161078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
    Peters H; Wang Y; Loof T; Martini S; Kron S; Krämer S; Neumayer HH
    Kidney Int; 2004 Dec; 66(6):2224-36. PubMed ID: 15569311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
    Koress C; Swan K; Kadowitz P
    Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Praliciguat and Soluble Guanylate Cyclase Stimulators for Peripheral Artery Disease.
    Kosmac K; Ismaeel A; Kim-Shapiro DB; McDermott MM
    Circ Res; 2023 Jan; 132(1):49-51. PubMed ID: 36603062
    [No Abstract]   [Full Text] [Related]  

  • 15. What is next in nitric oxide research? From cardiovascular system to cancer biology.
    Bian K; Murad F
    Nitric Oxide; 2014 Dec; 43():3-7. PubMed ID: 25153032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
    Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
    Stasch JP; Hobbs AJ
    Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.
    Mullershausen F; Russwurm M; Friebe A; Koesling D
    Circulation; 2004 Apr; 109(14):1711-3. PubMed ID: 15066950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
    Boerrigter G; Costello-Boerrigter LC; Cataliotti A; Lapp H; Stasch JP; Burnett JC
    Hypertension; 2007 May; 49(5):1128-33. PubMed ID: 17325237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of nitric oxide-sensitive guanylyl cyclase.
    Friebe A; Koesling D
    Circ Res; 2003 Jul; 93(2):96-105. PubMed ID: 12881475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.